Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly

Nicholas C. Cullen, Antoine Leuzy, Shorena Janelidze, Sebastian Palmqvist, Anna L. Svenningsson, Erik Stomrud, Jeffrey L. Dage, Niklas Mattsson-Carlgren, Oskar Hansson
doi: https://doi.org/10.1101/2021.01.22.21250293
Nicholas C. Cullen
1Lund University, Clinical Memory Research Unit, Lund, Sweden
B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Leuzy
1Lund University, Clinical Memory Research Unit, Lund, Sweden
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shorena Janelidze
1Lund University, Clinical Memory Research Unit, Lund, Sweden
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Palmqvist
1Lund University, Clinical Memory Research Unit, Lund, Sweden
2Memory Clinic, Skåne University Hospital, Lund, Sweden
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna L. Svenningsson
1Lund University, Clinical Memory Research Unit, Lund, Sweden
2Memory Clinic, Skåne University Hospital, Lund, Sweden
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Stomrud
1Lund University, Clinical Memory Research Unit, Lund, Sweden
2Memory Clinic, Skåne University Hospital, Lund, Sweden
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey L. Dage
3Eli Lilly and Company, Indianapolis, IN, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niklas Mattsson-Carlgren
1Lund University, Clinical Memory Research Unit, Lund, Sweden
4Department of Neurology, Skåne University Hospital, Lund, Sweden
5Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oskar Hansson
1Lund University, Clinical Memory Research Unit, Lund, Sweden
2Memory Clinic, Skåne University Hospital, Lund, Sweden
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Oskar.Hansson@med.lu.se Niklas.Mattsson-Carlgren@med.lu.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized in cognitively unimpaired (CU) elderly indviduals. We therefore tested if plasma measurements of amyloid-β (Aβ)42/40, phospho-tau217 (P-tau217), and neurofilament light (NfL) together predict clinical deterioration in 435 CU individuals followed for an average of 4.8 ±1.7 years in the BioFINDER study. A combination of all three plasma biomarkers and basic demographics best predicted change in the cognition (Pre-Alzheimer’s Clinical Composite; R2=0.14, 95% CI [0.12-0.17]; P<0.0001) and subsequent AD dementia (AUC=0.82, 95% CI [0.77-0.91], P<0.0001). In a simulated clinical trial, a screening algorithm combining all three plasma biomarkers would reduce the required sample size by 70% (95% CI [54-81]; P<0.001) with cognition as trial endpoint, and by 63% (95% CI [53-70], P<0.001) with subsequent AD dementia as trial endpoint. Plasma ATN biomarkers show usefulness in cognitively unimpaired populations and could make large clinical trials more feasible and cost-effective.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT01208675

Funding Statement

Work at the authors' research center supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383, and WCMM fellowship for Mattsson-Carlgren), the Medical Faculty at Lund University (WCMM fellowship for Mattsson-Carlgren), Region Skane (WCMM fellowship for Mattsson-Carlgren), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-745911, AF-930655), the Swedish Brain Foundation (FO2019-0326, FO2019-0029), The Parkinson foundation of Sweden (1280/20), the Skane University Hospital Foundation (2020-O000028), Regionalt Forskningsstod (2020-0314), the Swedish federal government under the ALF agreement (2018-Projekt0279), Stiftelsen Gamla Tjanarinnor (2019-00845), EU Joint Programme - Neurodegenerative Disease Research (2019-03401), The Bundy Academy, and The Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants gave written informed consent. Ethical approval was given by the Regional Ethical Committee in Lund, Sweden.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

For more information visit Biofinder.se. Relevant data from the study and code to perform the statistical analysis herein may be made available upon request from qualified researchers.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 22, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly
Nicholas C. Cullen, Antoine Leuzy, Shorena Janelidze, Sebastian Palmqvist, Anna L. Svenningsson, Erik Stomrud, Jeffrey L. Dage, Niklas Mattsson-Carlgren, Oskar Hansson
medRxiv 2021.01.22.21250293; doi: https://doi.org/10.1101/2021.01.22.21250293
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly
Nicholas C. Cullen, Antoine Leuzy, Shorena Janelidze, Sebastian Palmqvist, Anna L. Svenningsson, Erik Stomrud, Jeffrey L. Dage, Niklas Mattsson-Carlgren, Oskar Hansson
medRxiv 2021.01.22.21250293; doi: https://doi.org/10.1101/2021.01.22.21250293

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)